Release Date: May 07, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Veracyte Inc (NASDAQ:VCYT) reported a strong Q1 2025 with total revenue of $114.5 million, marking an 18% year-over-year growth. The company's core testing business showed robust performance with Decipher and Affirma delivering double-digit volume growth of 37% and 10% respectively. Veracyte Inc (NASDAQ:VCYT) ended the quarter with a strong balance sheet, holding $287 million in cash and short-term investments. The company is making significant strides in expanding its product offerings, including the launch of Decipher for metastatic prostate cancer and the upcoming launch of ProSigna as an LDT for the US breast cancer market. Veracyte Inc (NASDAQ:VCYT) is focused on cost reduction initiatives, transitioning Affirma onto a more cost-effective sequencing technology, which is expected to offset future reagent price increases.

Negative Points

Revenue growth for Affirma was lower than volume growth due to prior period collection benefits and a lab benefit manager's mistaken coverage policy change. The company is facing challenges with its French subsidiary, Veracyte SAS, which has filed for bankruptcy, impacting IVD product development timelines. There is uncertainty around the impact of tariffs and potential price increases from vendors, which could affect future costs. Veracyte Inc (NASDAQ:VCYT) is still adjudicating some claims related to the lab benefit manager's coverage policy change, which may take another quarter or two to resolve. The company's MRD platform, while promising, is still in the early stages with significant investment required to prove its value and achieve reimbursement.

Q & A Highlights

Warning! GuruFocus has detected 4 Warning Sign with VCYT.

Q: How do you feel about Veracyte's current portfolio, and is there a desire to expand it further? Also, how do you respond to those who believe the value of the MRD and nasal swab initiatives is limited? A: We are focused on portfolio management, ensuring investments have appropriate evidence and ROI. We've expanded from a single product to a broad portfolio, including new indications like lung and breast cancer. The MRD and nasal swab initiatives are in early stages, but we are confident in their potential given our track record and execution capabilities. (Mark Staley, CEO)

Q: Can you discuss how Veracyte is preparing organizationally for upcoming product launches and ensuring readiness? A: We focus on product development and evidence generation to support adoption and reimbursement. We plan commercial activities thoughtfully and scale sales teams as needed. Our analytical platform and channel synergies are key to our strategy, allowing us to launch new indications efficiently. (John Light, Chief Commercial Officer)

Story Continues

Q: Can you elaborate on the 20% increase in the ordering physician base for Decipher? Are these competitive wins or new to testing? A: The increase is a mix of new physicians, reactivated former users, and market share gains. We focus on penetrating larger accounts and expanding our reach within the physician base. (John Light, Chief Commercial Officer)

Q: How should we think about the components of growth for Affirma for the rest of the year, excluding prior period collection impacts? A: We expect strong volume growth, with prior period collections potentially being a headwind. We anticipate high single-digit revenue growth, driven by volume strength and product enhancements. (Rebecca Chambers, CFO)

Q: What is the initial response to the early launch of Decipher in the metastatic population, and what is the expected contribution in the back half of the year? A: The initial response has been positive, with physicians eager to use the test. We expect the launch to contribute to growth, similar to the biopsy launch in 2019, with the majority of growth coming from biopsy market penetration and share gains. (John Light, Chief Commercial Officer)

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments